Lifecore Biomedical, Inc., a an integrated CDMO, and PolyPeptide Laboratories, Inc., a global peptide contract development and manufacturer, entered a collaboration agreement aimed at providing an integrated solution for peptide-based pharmaceutical customers in the U.S.

The collaboration will leverage PolyPeptide’s peptide manufacturing and development services in combination with Lifecore’s formulation, fill/finish, and packaging services. The companies will work together to offer a seamless transition between drug substance and drug product, which aims to enable accelerated development timelines, reduced development costs and risks, and regulatory alignment with a fully U.S.-based supply chain.

“This collaboration brings together two leading organizations, each an expert in its field, to deliver value to peptide-based pharmaceutical developers. Together, we expect to optimize product development activities through a range of collaborative studies and assessments, and by streamlining the supply chain, aim to help customers meet their development milestones,” said Mark DaFonseca, chief commercial officer, Lifecore Biomedical.

“By aligning our technical and commercial strengths, we believe we are uniquely positioned to help customers navigate complex development challenges and bring innovative therapies to market faster. Together, the companies anticipate jointly supporting laboratory transfers, equipment comparability, method transfer and release testing, thus ensuring robust technical oversight and quality through the entire process,” added Trishul Shah, global director of business development and head of sales, PolyPeptide.

Video Q&A with Mark Dafonseca of Lifecore Biomedical